John Valliant

2022

In 2022, John Valliant earned a total compensation of $2.7M as Chief Executive Officer at Fusion Pharmaceuticals, a 16% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$238,119
Option Awards$1,881,826
Salary$595,284
Other$31,314
Total$2,746,543

Valliant received $1.9M in option awards, accounting for 69% of the total pay in 2022.

Valliant also received $238.1K in non-equity incentive plan, $595.3K in salary and $31.3K in other compensation.

Rankings

In 2022, John Valliant's compensation ranked 1,331st out of 5,683 executives tracked by ExecPay. In other words, Valliant earned more than 76.6% of executives.

ClassificationRankingPercentile
All
1,331
out of 5,683
77th
Division
Manufacturing
652
out of 3,091
79th
Major group
Chemicals And Allied Products
239
out of 1,406
83rd
Industry group
Drugs
218
out of 1,307
83rd
Industry
Biological Products, Except Diagnostic Substances
55
out of 295
81st
Source: SEC filing on April 27, 2023.

Valliant's colleagues

We found two more compensation records of executives who worked with John Valliant at Fusion Pharmaceuticals in 2022.

2022

John Crowley

Fusion Pharmaceuticals

Chief Financial Officer

2022

Eric Burak

Fusion Pharmaceuticals

Chief Technology Officer

News

In-depth

You may also like